

Prenatal Cell-Free DNA (cfDNA) Screening

NON-INVASIVE PRENATAL ANEUPLOIDY SCREEN BY CELL-FREE DNA SEQUENCING (3003043)

Why prenatal cell-free DNA (cfDNA) screening?*

- Prenatal cell-free DNA (cfDNA) screening is the most sensitive and specific testing available to screen for common chromosome aneuploidies such as Down syndrome.
- Noninvasive, with no risk of miscarriage, prenatal cfDNA screening enables analysis of genomic cfDNA circulating in the maternal bloodstream and requires only one blood sample.
- Multiple professional guidelines support the use of prenatal cfDNA screening for all pregnant individuals.[1,2]

Why ARUP?

- Competitive turnaround time (TAT) and pricing
- Comprehensive prenatal screening and diagnostic test menu to meet your needs
- Support from our integrated team of board-certified laboratory geneticists and genetic counselors, who specialize in prenatal genetics and can aid in test selection and result interpretation
- Streamlined workflow for your hospital lab to help stop leakage
- Results flow directly into the electronic medical record (EMR) once you are set up for ordering and reporting via your interface
- Opportunity for integration with a comprehensive test menu that includes a suite of testing related to women's health (e.g., carrier screening, maternal serum screening, prenatal screening, and prenatal diagnostic testing)
- Straightforward billing consistent with nongenetic lab tests

For more information, visit aruplab.com/cfDNA or contact your local ARUP account executive.

References:

1. Screening for fetal chromosomal abnormalities: ACOG Practice Bulletin Summary, Number 226. *Obstet Gynecol.* 2020;136(4):859-867.
2. Practice Bulletin No. 162: Prenatal diagnostic testing for genetic disorders. *Obstet Gynecol.* 2016;127(5):e108-e122.

* Prenatal cfDNA screening, previously referred to as noninvasive prenatal testing (NIPT).